View source for 4z2l


==Serratia marcescens Chitinase B complexed with macrolide inhibitor 33==
<StructureSection load='4z2l' size='340' side='right'caption='[[4z2l]], [[Resolution|resolution]] 2.30&Aring;' scene=''>
== Structural highlights ==
<table><tr><td colspan='2'>[[4z2l]] is a 1 chain structure with sequence from [https://en.wikipedia.org/wiki/Serratia_marcescens Serratia marcescens]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=4Z2L OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=4Z2L FirstGlance]. <br>
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.3&#8491;</td></tr>
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=CL:CHLORIDE+ION'>CL</scene>, <scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=M6F:(3R,4S,5S,6R,7R,9R,10S,11S,12R,13S,14R)-14-ETHYL-7,10,12,13-TETRAHYDROXY-3,5,7,9,11,13-HEXAMETHYL-2-OXO-6-(PROP-2-YN-1-YLOXY)OXACYCLOTETRADECAN-4-YL+{3-[N-(METHYLCARBAMOYL)CARBAMIMIDAMIDO]PROPYL}CARBAMATE'>M6F</scene></td></tr>
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=4z2l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4z2l OCA], [https://pdbe.org/4z2l PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=4z2l RCSB], [https://www.ebi.ac.uk/pdbsum/4z2l PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=4z2l ProSAT]</span></td></tr>
</table>
== Function ==
[https://www.uniprot.org/uniprot/CHIB_SERMA CHIB_SERMA] 
<div style="background-color:#fffaf0;">
== Publication Abstract from PubMed ==
Argifin, a 17-membered pentapeptide, inhibits chitinase. As argifin has properties that render it unsuitable as a drug development candidate, we devised a mechanism to create the structural component of argifin that bestows the chitinase inhibition and introduce it into a 14-membered macrolide scaffold. Here we describe (1) the designed macrolide, which exhibits approximately 200-fold more potent chitinase inhibition than argifin, (2) the binding modes of the macrolide with Serratia marcescens chitinase B, and (3) the computed analysis explaining the reason for derivatives displaying increased inhibition compared to argifin, the macrolide aglycone displaying inhibition in a nanomolar range. This promises a class of chitinase inhibitors with novel skeletons, providing innovative insight for drug design and the use of macrolides as adaptable, flexible templates for use in drug discovery research and development.

Creation of Customized Bioactivity within a 14-Membered Macrolide Scaffold: Design, Synthesis, and Biological Evaluation Using a Family-18 Chitinase.,Sugawara A, Maita N, Gouda H, Yamamoto T, Hirose T, Kimura S, Saito Y, Nakano H, Kasai T, Nakano H, Shiomi K, Hirono S, Watanabe T, Taniguchi H, Omura S, Sunazuka T J Med Chem. 2015 Jun 25;58(12):4984-4997. Epub 2015 Jun 12. PMID:26030312<ref>PMID:26030312</ref>

From MEDLINE&reg;/PubMed&reg;, a database of the U.S. National Library of Medicine.<br>
</div>
<div class="pdbe-citations 4z2l" style="background-color:#fffaf0;"></div>

==See Also==
*[[Chitinase 3D structures|Chitinase 3D structures]]
== References ==
<references/>
__TOC__
</StructureSection>
[[Category: Large Structures]]
[[Category: Serratia marcescens]]
[[Category: Maita N]]
[[Category: Sugawara A]]
[[Category: Sunazuka T]]